Maze Therapeutics, Inc.
MAZE · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: 4 ·
Latest disclosures
-
Coloma Jason V: Form 4
Insider disclosure · Filed · Report period 01 Oct 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- MAZE · 578784100 - Common Stock, $0.001 par value per share
Company details and SEC sources
CIK 0001842295 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- MAZE on Nasdaq
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 171 Oyster Point Boulevard, Suite 300, South San Francisco, CA, 94080
- Incorporated in
- DE
- Fiscal year end
- 31 December
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields